For a long time, the healthcare sector of the U.S. stock market, with its stable growth from leading companies and substantial dividends, has been widely regarded as a typical defensive sector. However, this traditional market positioning is undergoing a profound transformation. After years of underperformance relative to the broader market, the sector staged a strong rebound in the previous quarter, becoming the best-performing industry within the S&P 500 index. This change is attributed to multiple factors: tariff agreements reached with the government, active industry merger and acquisition activity, and technological breakthroughs represented by the new generation of weight-loss drugs. Meanwhile, facing the pressure of high valuations in technology stocks, some investors have begun to shift their focus to alternative growth opportunities in sectors like healthcare.
Many investment professionals anticipate that this upward momentum is likely to continue into 2026. Analysts point out that investors are flocking to healthcare stocks they perceive as having value and higher return potential, thereby endowing the sector with more aggressive investment characteristics. However, investing in the healthcare sector in 2026 will place greater emphasis on stock-picking skills. Looking ahead to 2026, the following three core trends warrant close attention.
Weight-loss drugs have been the focal point of the healthcare field over the past three years, a trend expected to persist into 2026, with progress in oral obesity treatments being a key catalyst. The U.S. Food and Drug Administration (FDA) is expected to decide by early 2026 whether to approve Eli Lilly’s (LLY) oral drug, while a competing product from Novo Nordisk (NVO) has already received approval. Goldman Sachs predicts that the sequential approval of related drugs will unlock new market growth, with the market size potentially reaching $95 billion by 2030. Furthermore, starting in 2026, under relevant agreements, weight-loss drug injectables will be included in Medicare coverage, thereby benefiting a broader patient population. Portfolio manager Kevin Gade believes that with increased production capacity, innovative breakthroughs like oral medications, and successful entry into the core medical insurance market, this segment will maintain rapid growth.
The intensive merger and acquisition activity in the second half of 2025, combined with market expectations that Federal Reserve interest rate cuts will lower financing costs, has injected confidence into the industry’s recovery. Data shows that as of December 1 last year, there were 28 announced or completed healthcare M&A deals exceeding $10 billion, with a total value surpassing $103 billion, far exceeding the levels seen in 2024. Arda Ural of Ernst & Young stated that this instills more confidence, rather than just hope, regarding the industry’s prospects for 2026.
Simultaneously, the initial public offering (IPO) market has also shown signs of recovery, with biotechnology companies performing notably well. The total funds raised by biotech IPOs launched in the U.S. market in 2025 increased by 61% year-over-year. The Nasdaq Biotechnology Index rebounding over 50% from its low and hitting a record high in December further corroborates the market’s enthusiasm for this field.
In contrast, the growth prospects for health insurance companies face more uncertainties. Insurers primarily serving Medicare Advantage plans, while previously hopeful for policy subsidies, are actually facing pressure from rising costs in both Medicare and Affordable Care Act businesses. Industry giants such as Molina Healthcare Inc. (MOH), UnitedHealth Group (UNH), and Centene Corporation (CNC) all experienced significant stock price declines in 2025.
Although some investors, like Christopher Hart, see significant value opportunities in the sector, they remain cautious and would consider increasing investment only when the industry’s earnings outlook becomes clearer.
